Why a strategist who previously thought inflation was contained now sees potential for aggressive Fed rate hikes
Albert Edwards of Société Générale says today’s gasoline prices are more closely aligned with crude-oil prices of $150 a barrel than current levels. For diesel, it’s even more dramatic.
At a glance
- $EW today−1.57%last $105.43
- Vs industry peers−1.06 pts6-peer median −0.51% · behind
- Since Sep 16+18.1%from the first trade after the story
- 52-week range2.4% below high$74.66 – $108.00
- Last reported profit$307.5Mquarter to Sep 30, 2026 · 10-Q
- In the headline$150Amount
Nothing reported about Edwards Lifesciences across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Options price an average move of ±6.4% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: There is a hard number in this story ($150) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $EW -1.57% in the latest session.
- Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Where the stock stands
Edwards Lifesciences Corporatio ($EW) slipped 1.57% to $105.43 in the latest session. Over the past month it is up 20.9%. That leaves it 2.4% below its 52-week high of $108.00 and 41% above its low of $74.66, close to the top of its range. The high sits 45% above the low, a moderate range for a year.
What the filings say
In its latest report (10-Q, filed Nov 4, 2026), $EW earned $307.5M over the quarter to Sep 30, 2026 on revenue of $1.72B (-1.5% QoQ). Operations brought in $1.27B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $1.07B. It carried $598.8M of debt against $3.11B of cash on Sep 30, 2026 — net cash of $2.51B. Its most recent filings before this story: 8-K on Aug 28, 2026, 10-Q on Aug 4, 2026, 8-K on Jul 23, 2026. Figures are as filed with the SEC; the $EW page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed 2 newer stories on Edwards Lifesciences Corporatio in the last 30 days, 2 of them this week. By their wording, 0 read bullish, 2 neutral and 0 bearish.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
Coming up
Monthly options expiration in 3 days and FOMC decision in 22 days. These dates were set well before this story broke. The nearest is 3 days away, so fresh numbers are close.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $EW page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $EW: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
MarketWatch published this on September 16, 2026. $EW has moved +18.09% ($89.28 to $105.43). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.